Results 111 to 115 of about 1,506 (115)
Some of the next articles are maybe not open access.

Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer

Cancer, 2023
Yi-Long Wu, Huaqiu Shi
exaly  

Green One-Pot Chemo-Enzymatic Synthesis of a Key Chiral Amine Intermediate: Useful to Pralsetinib Synthesis

ChemistrySelect, 2023
exaly  

Top bar navigation

Frontiers in Pharmacology
Qiong Jie
exaly  

Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

Oral Oncology
Nai-Si Huang, Qing-Hai Ji, Jia-Ying Chen
exaly  

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer

Future Oncology
Sorrel Wolowacz   +2 more
exaly  
selpercatinib
ret fusion
case report
nsclc
ret
lung cancer
thyroid cancer
tyrosine kinase inhibitors
lung adenocarcinoma
previous   10  11  12  

Home - About - Disclaimer - Privacy